Cargando…

Circulating CD137(+) T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients

Pembrolizumab, an anti-PD-1 antibody, has been approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma ((R/M) HNSCC). However, only a minority of patients benefit from immunotherapy, which highlights the need to identify novel biomarkers to optimize treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cirillo, Alessio, Zizzari, Ilaria Grazia, Botticelli, Andrea, Strigari, Lidia, Rahimi, Hassan, Scagnoli, Simone, Scirocchi, Fabio, Pernazza, Angelina, Pace, Angelica, Cerbelli, Bruna, d’Amati, Giulia, Marchetti, Paolo, Nuti, Marianna, Rughetti, Aurelia, Napoletano, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138766/ https://www.ncbi.nlm.nih.gov/pubmed/37108276 http://dx.doi.org/10.3390/ijms24087114

Ejemplares similares

The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
por: Botticelli, Andrea, et al.
Publicado: (2021)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma
por: Pace, Angelica, et al.
Publicado: (2022)

IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells
por: Ugolini, Alessio, et al.
Publicado: (2020)

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
por: Pace, Angelica, et al.
Publicado: (2023)

Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer
por: Cerbelli, Bruna, et al.
Publicado: (2020)

Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity
por: Ceccarelli, Fulvia, et al.
Publicado: (2023)

Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL)
por: Napoletano, Chiara, et al.
Publicado: (2020)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
por: Mezi, Silvia, et al.
Publicado: (2021)

A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors
por: Mezi, Silvia, et al.
Publicado: (2023)

Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
por: Cerbelli, Bruna, et al.
Publicado: (2022)

MGL Receptor and Immunity: When the Ligand Can Make the Difference
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2015)

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
por: Botticelli, Andrea, et al.
Publicado: (2020)

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
por: Cerbelli, Bruna, et al.
Publicado: (2017)

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2020)

The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2015)

Atypical cellular neurothekeoma (ACN) of the elderly: case report and brief review of the literature
por: D’Alessandris, Nicoletta, et al.
Publicado: (2020)

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets
por: Napoletano, Chiara, et al.
Publicado: (2019)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach
por: Botticelli, Andrea, et al.
Publicado: (2023)

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
por: Botticelli, Andrea, et al.
Publicado: (2019)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
por: Botticelli, Andrea, et al.
Publicado: (2018)

Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response
por: Zizzari, Ilaria G, et al.
Publicado: (2013)

The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2022)

Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
por: Bellati, Filippo, et al.
Publicado: (2011)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial
por: ANTONILLI, MORENA, et al.
Publicado: (2016)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma
por: Rahimi Koshkaki, Hassan, et al.
Publicado: (2020)

Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells
por: Battisti, Federico, et al.
Publicado: (2017)

HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2011)

Extremely late-onset pulmonary metastasis from uterine PEComa
por: Ascione, Andrea, et al.
Publicado: (2022)

Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells
por: Dionisi, Marco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_72hbfbrqf9tbe9bcfscuj72v4b